Atlas Trials

Y-mAbs Therapeutics

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Y-mAbs Therapeutics

RecordFirmDate
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05994157)Y-mAbs Therapeutics2025-04-21
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 (NCT05130255)Y-mAbs Therapeutics2022-11-17
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) (NCT04315246)Y-mAbs Therapeutics2022-08-31
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT05077423)Y-mAbs Therapeutics2022-05-25
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma (NCT05063357)Y-mAbs Therapeutics2022-03-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. (NCT04909515)Y-mAbs Therapeutics2021-12-02
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (NCT04167618)Y-mAbs Therapeutics2021-09-30
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer (NCT04750239)Y-mAbs Therapeutics2021-08-17
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers (NCT03860207)Y-mAbs Therapeutics2019-02-22
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases (NCT03275402)Y-mAbs Therapeutics2018-12-11
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow (NCT03363373)Y-mAbs Therapeutics2018-04-03

Track Y-mAbs Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.